[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yunnan Cancer Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":396},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,40,62,80,106,132,155,176,191,206,221,241,260,281,299,318,340,356,375],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100644613","prediction-of-neoadjuvant-therapy-efficacy-and-prognosis-for-breast-cancer-based-on-multimodal-data-100644613",false,"NCT07671690","Prediction of Neoadjuvant Therapy Efficacy and Prognosis for Breast Cancer Based on Multimodal Data","Prediction of Neoadjuvant Therapy Efficacy and Prognosis for Breast Cancer Based on Multimodal Data: A Multicenter Retrospective and Prospective Validation","Inclusion Criteria:\n\n1. Histopathologically confirmed invasive breast cancer;\n2. Planned to receive a full course of neoadjuvant therapy;\n3. Complete baseline imaging data (MRI\u002Fultrasound\u002Fmammography) and core needle pathology results available.\n\nExclusion Criteria:\n\n1. Previous history of ipsilateral breast cancer or chest radiotherapy;\n2. Distant metastasis (Stage IV);\n3. Poor image quality or missing clinical data exceeding 20%.","FEMALE","18 Years","80 Years",{"count":20,"type":21},1800,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to develop a multimodal deep learning model integrating MRI, ultrasound, digital pathology and clinical information based on multicenter retrospective data. To externally validate the model in an independent prospective cohort, and evaluate its accuracy in predicting pathological complete response (pCR), 3-year and 5-year disease-free survival (DFS). To establish visual tools such as nomograms, assisting clinicians in identifying patients with chemoresistance and facilitating individualized de-escalation or escalation treatment strategies.",[27],"Breast Carcinoma","NOT_YET_RECRUITING","2026-06-22",{"date":31,"type":32},"2026-06-26","ACTUAL",{"date":34,"type":21},"2026-06-01",{"date":36,"type":21},"2029-06-30",{"name":38,"class":39},"Yunnan Cancer Hospital","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":46,"targetDuration":4,"studyType":22,"phases":48,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},"100640244","the-value-of-time-dependent-diffusion-mri-and-magnetic-resonance-elastography-in-the-precise-diagnosis-and-efficacy-assessment-of-breast-cancer-100640244","NCT07608081","The Value of Time-Dependent Diffusion MRI and Magnetic Resonance Elastography in the Precise Diagnosis and Efficacy Assessment of Breast Cancer","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. Female patients with BI-RADS class 4 or above breast lesions detected by mammography or ultrasound\n3. Perform breast new technology MRI examination (ultra fast DCE-MRI、OGSE 、MRE、vMRE)within one week before biopsy or surgery\n\nExclusion Criteria:\n\n1. Previously received breast radiotherapy, chemotherapy, surgery, or targeted therapy\n2. Unable to cooperate in completing MRI examination\n3. The image data contains serious artifacts (such as motion artifacts and metal artifacts), making it impossible to measure parameters\n4. The lesion cannot be clearly identified and outlined on the image\n5. Pregnant and lactating women\n6. Combined with severe liver, liver, and kidney diseases, coagulation dysfunction, or other malignant tumors",{"count":47,"type":21},1000,[24],"We consecutively enrolled patients presenting with breast space-occupying lesions at our hospital. Medical imaging data from simultaneously acquired ultrafast DCE-MRI, time-dependent diffusion MRI (TDD-MRI), magnetic resonance elastography (MRE), andvirtual magnetic resonance elastography(vMRE), along with clinical and pathological data, were collected. The study aims to evaluate and explore the clinical application value of these multimodal imaging techniques in the precision diagnosis, treatment, and prognosis of breast cancer. The findings are intended to provide a robust imaging basis for formulating and adjusting more precise, individualized treatment plans and prognostic assessments for patients. Ultimately, this research seeks to improve patient quality of life, optimize the allocation of medical resources, and advance the development of precision medicine.",[51],"Breast Cancer","RECRUITING","2026-05-19",{"date":55,"type":32},"2026-05-27",{"date":57,"type":32},"2025-10-01",{"date":59,"type":21},"2027-10-01",{"name":38,"class":39},1,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":71,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":79,"locationsCount":4},"100640894","research-on-the-whole-process-intelligent-diagnosis-and-treatment-of-digital-breast-tomosynthesis-based-on-deep-learning-100640894","NCT07605195","Research on the Whole-Process Intelligent Diagnosis and Treatment of Digital Breast Tomosynthesis Based on Deep Learning","Research on the Whole-Process Intelligent Diagnosis and Treatment of Digital Breast Tomosynthesis Based on Deep Learning: Multicenter Retrospective and Prospective Validation","Inclusion Criteria\n\n1. Female patients aged ≥ 18 years.\n2. Complete bilateral digital breast tomosynthesis (DBT) images available, including craniocaudal (CC) and mediolateral oblique (MLO) views.\n3. Confirmed pathological diagnosis (core needle biopsy or surgical resection) serving as the reference standard; or benign lesions with stable findings on follow-up for more than 2 years.\n4. (For the efficacy prediction subgroup) Patients who received complete neoadjuvant therapy and had postoperative pathological results.\n\n2\\. Exclusion Criteria\n\n1. Poor image quality with severe artifacts that precluded reliable analysis.\n2. History of previous breast surgery or radiotherapy (except for the recurrence risk subgroup).\n3. Incomplete clinical or pathological data.",{"count":70,"type":21},5000,[24],"This study aims to construct a multi-task deep learning model system to mine deep features in DBT images, so as to achieve accurate detection of breast lesions, differential diagnosis of benign and malignant (especially for the challenging BI-RADS 4A category), prediction of molecular subtypes, and evaluation of neoadjuvant chemotherapy (NAC) efficacy, providing an imaging basis for precision medicine.",[27],{"date":75,"type":32},"2026-05-22",{"date":77,"type":21},"2026-05-20",{"date":36,"type":21},{"name":38,"class":39},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":97,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":61},"100604826","rapid-assessment-of-sentinel-lymph-node-metastasis-status-using-a-pan-ck-targeting-nir-ii-fluorescent-probe-in-breast-cancer-100604826","NCT07154563","Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Cancer","NIR-II","Inclusion Criteria:\n\n* Adult patients between 18-75 years of age\n* Patients presenting with a breast nodule or mass presumed to be resectable on pre-operative assessment\n* Breast cancer patients who are scheduled to undergo sentinel lymph node biopsy or axillary lymph node dissection;\n* Good operative candidate\n* Subject capable of giving informed consent and participating in the process of consent\n\nExclusion Criteria:\n\n* Patients unable to participate in the consent process\n* Patients had contraindications to surgery, such as serious cardiopulmonary disease, coagulation dysfunction, etc","75 Years",{"count":89,"type":21},60,"OBSERVATIONAL","Breast malignant tumors are a serious threat to women's health, and the current treatment for breast malignant tumors is still dominated by surgery, but the problems faced by patients after surgery such as edema and tumor recurrence are still relatively common, and the high recurrence rate and the occurrence of postoperative complications are closely related to the removal of metastatic lymph nodes during surgery. Therefore, accurate assessment of sentinel lymph node (SLN) metastases is essential to determine the extent of axillary lymph node dissection (ALND) and minimize complications. In this study, we developed a new technique that can rapidly distinguish between metastatic lymph nodes and normal sentinel lymph nodes (SLNs) in breast cancer patients. Briefly, fresh tissue is incubated with the probe and imaged immediately after intraoperative sentinel lymph node resection to identify the metastatic status of SLN. The accuracy of fluorescence imaging is confirmed by pathological diagnosis.",[93,94,95,96],"Breast Cancer Metastatic","Sentinel Lymph Node","Sentinel Lymph Node Biopsy (SLNB)","Metastasis",[85,51,94,96],"2025-08-27",{"date":100,"type":32},"2025-09-04",{"date":102,"type":32},"2025-02-01",{"date":104,"type":21},"2026-12-01",{"name":38,"class":39},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":87,"enrollmentInfo":112,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":114,"conditions":115,"keywords":119,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":61},"100594366","epcam-targeted-surface-enhanced-raman-spectroscopy-nanotags-for-rapid-evaluation-of-surgical-margins-and-sentinel-lymph-node-metastasis-status-in-breast-cancers-100594366","NCT07018505","EpCAM-Targeted Surface-Enhanced Raman Spectroscopy Nanotags for Rapid Evaluation of Surgical Margins and Sentinel Lymph Node Metastasis Status in Breast Cancers","Inclusion Criteria:\n\n* Adult patients between 18-75 years of age\n* Female\n* Patients presenting with a breast cancer to be resectable on pre-operative assessment\n* Good operative candidate\n* Subject capable of giving informed consent and participating in the process of consent\n\nExclusion Criteria:\n\n* Patients unable to participate in the consent process\n* Patients had contraindications to surgery, such as serious cardiopulmonary disease, coagulation dysfunction, etc\n* Other conditions that the researcher considers inappropriate to participate in the study",{"count":113,"type":21},40,"For early breast cancer patients, breast-conserving surgery and sentinel lymph node biopsy have emerged as the cornerstone of precision oncology, harmonizing oncologic efficacy with the preservation of breast cosmetics and axillary function. However, conventional margin evaluation relies on subjective experience, leading to positive margin rates of 15%-50% Additionally, sentinel lymph node biopsy faces inherent technical limitations, including prolonged procedural time and significant false-negative rates in detecting micro-metastases. To overcome these challenges, the investigators will introduce a stable \"sandwich\" EpCAM-targeted surface-enhanced Raman spectroscopy (SERS) detection system to provide rapid evaluation of surgical margins and sentinel lymph node (SLN) metastasis status. In brief, a portion of resected tissue will be immediately homogenized by grinding, and the tissue homogenate will then be analyzed using this detection system to determine its histological characteristics. Pathological confirmation will further validate the method. This approach aims to improve the accuracy and efficiency of intraoperative assessment of breast-conserving surgical margins and SLN status, thereby effectively reducing local recurrence rates and complications.",[94,116,117,118],"Breast Cancers","Metastases","Margin Assessment",[94,120,121,122,123],"Surface Enhanced Raman Spectroscopy","EpCAM","Breast cancers","Surgical margin","2025-06-04",{"date":126,"type":32},"2025-06-12",{"date":128,"type":21},"2025-06-15",{"date":130,"type":21},"2026-07-01",{"name":38,"class":39},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":139,"minAge":17,"maxAge":18,"enrollmentInfo":140,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":61},"100590849","trop2-targeting-nir-ii-molecular-probe-for-guided-identification-of-non-muscle-invasive-bladder-cancer-100590849","NCT06972771","Trop2-targeting NIR-II Molecular Probe for Guided Identification of Non-Muscle-Invasive Bladder Cancer","Trop2-targeting the Second Near-Infrared Fluorescence(NIR-II ) Molecular Probe for Guided Identification of Non-Muscle-Invasive Bladder Cancer","Inclusion Criteria:\n\n* Adult patients between 18-80 years of age\n* Patients with suspected non-muscle-invasive bladder cancer scheduled to undergo surgical intervention.\n* Good operative candidate\n* Subject capable of giving informed consent and participating in the process of consent\n\nExclusion Criteria:\n\n* Patients unable to participate in the consent process\n* Patients had contraindications to surgery, such as serious cardiopulmonary disease, coagulation dysfunction, etc\n* Other conditions that the researcher considers inappropriate to participate in the study","ALL",{"count":141,"type":21},30,"Bladder cancer ranks as the fourth most common malignancy among males the United States . Approximately 75% of patients present with non-muscle-invasive bladder cancer (NMIBC). For the diagnosis and treatment of NMIBC, current guidelines widely recommend white light cystoscopy (WLC) and transurethral resection of the bladder tumor (TURBT). Unfortunately, up to 70% of patients with NMIBC experience intravesical recurrence within five years of their initial treatment. The high recurrence rates necessitate long-term surveillance for most NMIBC patients, making it one of the most costly malignancies to manage. In fact, a higher risk of disease recurrence is also associated with the now widely used WLC and TURBT, which cause false-negative investigations with an inadequate resection or residual tumor, especially when urothelial tumors present as carcinoma in situ or multiple.\n\nIndocyanine green (ICG)-based the second near-infrared (NIR-II) fluorescence imaging offers real-time visualization during surgery, potentially reducing residual tumor. Herein, the investigators will introduce a novel NIR-II probe, TTP-ICG, based on a Trop2-targeting peptide (TTP) and an approach which enables differentiation between cancer and para-cancer . In brief, tissues will be soaked in TTP-ICG after resection, and their histological characterization will be determined under NIR-II fluorescence imaging. Pathological confirmation will further validate our approach.\n\nTo explore the conditions for the future in vivo real-time identification of NMIBC during NIR-II fluorescence -guided surgery.",[144],"Non-Muscle-Invasive Bladder Cancer",[146,85,144],"Trop2","2025-05-23",{"date":149,"type":32},"2025-05-30",{"date":151,"type":32},"2025-01-17",{"date":153,"type":21},"2025-11-30",{"name":38,"class":39},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":139,"minAge":17,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":61},"100591203","the-application-value-of-spectral-ct-in-the-accurate-staging-of-colorectal-cancer-100591203","NCT06977373","The Application Value of Spectral CT in the Accurate Staging of Colorectal Cancer","Inclusion Criteria:\n\n1. Undergo a contrast-enhanced Quark Spectral CT scan of the lower abdomen\u002Fpelvis within 1 week before treatment.\n2. Age \\> 18 years.\n3. Patients suspected of having colorectal cancer.\n4. Patients who have signed the informed consent form.\n\nExclusion Criteria:\n\n1. Severe cardiac, pulmonary, or renal insufficiency.\n2. Allergy to iodine-based contrast agents.\n3. Inability to cooperate with the CT examination.\n4. Poor image quality of the Quark Spectral CT scan.\n5. Women who are pregnant or breastfeeding.","90 Years",{"count":163,"type":21},150,[24],"Spectral CT was used to prospectively collect medical images and clinical data related to colorectal cancer, evaluate the effect of image quality in the diagnosis of colorectal cancer, and evaluate the application value in the accurate staging of colorectal cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.",[167],"Colorectal Cancer","2025-05-16",{"date":170,"type":32},"2025-05-18",{"date":172,"type":21},"2025-06-01",{"date":174,"type":21},"2026-05-31",{"name":38,"class":39},{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":139,"minAge":17,"maxAge":18,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":187,"startDateStruct":188,"completionDateStruct":189,"leadSponsor":190,"locationsCount":61},"100591205","the-application-value-of-spectral-ct-in-the-accurate-staging-of-liver-cancer-100591205","NCT06977399","The Application Value of Spectral CT in the Accurate Staging of Liver Cancer","Inclusion Criteria:\n\n1. Undergo a contrast-enhanced Quark Spectral CT scan of the lower abdomen\u002Fpelvis within 1 week before treatment.\n2. Age \\> 18 years.\n3. Patients suspected of having liver cancer.\n4. Patients who have signed the informed consent form.\n\nExclusion Criteria:\n\n1. Severe cardiac, pulmonary, or renal insufficiency.\n2. Allergy to iodine-based contrast agents.\n3. Inability to cooperate with the CT examination.\n4. Poor image quality of the Quark Spectral CT scan.\n5. Women who are pregnant or breastfeeding.",{"count":163,"type":21},[24],"Spectral CT was used to prospectively collect medical images and clinical data related to liver cancer, evaluate the effect of image quality in the diagnosis of liver cancer, and evaluate the application value in the accurate staging of liver cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.",[186],"Liver Cancer",{"date":170,"type":32},{"date":172,"type":21},{"date":174,"type":21},{"name":38,"class":39},{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":139,"minAge":17,"maxAge":18,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":198,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":204,"leadSponsor":205,"locationsCount":61},"100591204","the-application-value-of-spectral-ct-in-the-accurate-staging-of-gastric-cancer-100591204","NCT06977386","The Application Value of Spectral CT in the Accurate Staging of Gastric Cancer","Inclusion Criteria:\n\n* (a)Patients with pathologically confirmed gastric cancer;\n* (b) aged ≥ 18 years old;\n* (c) have not received chemoradiotherapy or surgery.\n\nExclusion Criteria:\n\n* (a)Combined with other primary tumors;\n* (b) The image quality does not meet the diagnostic criteria;\n* (c)Those who cannot tolerate CT examination.",{"count":163,"type":21},[24],"Spectral CT was used to prospectively collect medical images and clinical data related to gastric cancer, evaluate the effect of image quality in the diagnosis of gastric cancer, and evaluate the application value in the accurate staging of gastric cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.",[201],"Gastric Cancer",{"date":170,"type":32},{"date":172,"type":21},{"date":174,"type":21},{"name":38,"class":39},{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":212,"targetDuration":4,"studyType":22,"phases":213,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":217,"startDateStruct":218,"completionDateStruct":219,"leadSponsor":220,"locationsCount":4},"100591206","the-application-value-of-spectral-ct-in-the-accurate-staging-of-breast-cancer-100591206","NCT06977412","The Application Value of Spectral CT in the Accurate Staging of Breast Cancer","Inclusion Criteria:\n\n* (a) Chest quark energy spectrum CT examination was performed within 1 week before treatment\n* (b) Age ≥ 18\n* (c) Suspected breast cancer patients\n* (d) Patients who signed informed consent\n\nExclusion Criteria:\n\n* (a) Severe cardiac, pulmonary and renal insufficiency\n* (b) Allergic to iodine contrast media\n* (c) Unable to cooperate to complete CT examination\n* (d) Quark spectrum CT image is poor and cannot be used\n* (e) Male, pregnant and lactating female\n* (f) Combined with other tumor history\n* (g) Incomplete clinical and pathological data\n* (h) Pathologically confirmed non breast cancer",{"count":163,"type":21},[24],"Spectral CT was used to prospectively collect medical images and clinical data related to breast cancer, evaluate the effect of image quality in the diagnosis of breast cancer, and evaluate the application value in the accurate staging of breast cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.",[216],"Breast Adenocarcinoma",{"date":170,"type":32},{"date":172,"type":21},{"date":174,"type":21},{"name":38,"class":39},{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":139,"minAge":17,"maxAge":18,"enrollmentInfo":227,"targetDuration":4,"studyType":22,"phases":229,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":61},"100574175","dce-mri-based-on-4d-free-breathing-for-predicting-preoperative-neoadjuvant-chemoradiotherapy-for-esophageal-cancer-100574175","NCT06755866","DCE-MRI Based on 4D Free Breathing for Predicting Preoperative Neoadjuvant Chemoradiotherapy for Esophageal Cancer","Inclusion Criteria:\n\n1. Be 18 years of age and older;\n2. First diagnosis of esophageal squamous cell carcinoma confirmed by histopathological biopsy;\n3. The clinical stage is cT1b\\~cT2N+; or the clinical stage is cT3\\~cT4 any N, (thoracic esophageal cancer, esophagogastric junction cancer);\n4. There are no contraindications to MRI examination\n\nExclusion Criteria:\n\n1. Have other primary tumors;\n2. The image quality does not meet the diagnostic criteria;\n3. Those who do not cooperate with the inspection;\n4. Patients who have received prior chemoradiotherapy",{"count":228,"type":21},135,[24],"To prospectively collect medical images and clinical data related to esophageal cancer using 4D Free Breathing DCE-MRI technology, to evaluate the image quality in the diagnosis of esophageal cancer, and to predict the efficacy of preoperative neoadjuvant chemoradiotherapy for esophageal cancer.",[232],"Esophageal Cancer","2024-12-24",{"date":235,"type":32},"2025-01-01",{"date":237,"type":32},"2024-11-26",{"date":239,"type":21},"2026-07-31",{"name":38,"class":39},{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":139,"minAge":17,"maxAge":87,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":249,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":259,"locationsCount":61},"100573110","application-of-dce-mri-based-on-4d-freebreathing-in-predicting-the-efficacy-of-immune-and-targeted-therapy-in-lung-cancer-100573110","NCT06742021","Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer","Inclusion Criteria:\n\n1. Tumor size greater than 2 cm\n2. Age between 18 and 75 years\n\nExclusion Criteria:\n\n1. Presence of MRI contraindications (e.g., metal implants, pacemaker implantation, etc.)\n2. Allergy to gadolinium contrast agents\n3. Lesions difficult to delineate on images due to conditions such as atelectasis or diffuse lesions",{"count":248,"type":21},195,[24],"This study aims to address the challenge of predicting the efficacy of targeted and immunotherapy in lung cancer patients. By utilizing two DCE-MRI images-one before treatment and one after one treatment cycle-along with the patients' clinical and pathological information, we aim to achieve accurate prediction of the therapeutic efficacy of targeted and immunotherapy in lung cancer patients.",[252],"Lung Cancer","2024-12-15",{"date":255,"type":32},"2024-12-19",{"date":257,"type":32},"2024-11-11",{"date":239,"type":21},{"name":38,"class":39},{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":267,"sex":139,"minAge":17,"maxAge":18,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":270,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":61},"100572579","study-on-the-value-of-three-dwi-scanning-sequences-in-staging-of-gastric-cancer-100572579","NCT06735105","Study on the Value of Three DWI Scanning Sequences in Staging of Gastric Cancer","Comparative Study on the Value of Three DWI Scan Sequences of 3.0T Magnetic Resonance in Staging of Gastric Cancer","Inclusion Criteria:\n\n1. The patient was diagnosed with gastric cancer by pathological biopsy\n2. No biopsy was taken within 1 week before MR Examination to rule out the effect of bleeding on the image\n3. No contraindications for MRI examination; And exclude serious heart, liver, kidney, cerebrovascular diseases.\n\nExclusion Criteria:\n\n1. The image quality cannot meet the diagnostic criteria;\n2. Patients could not tolerate MRI examination, resulting in incomplete MR-related sequence image data.",true,{"count":269,"type":21},129,[24],"Accurate staging is critical for effective gastric cancer treatment planning. Conventional DWI (C-DWI) has limitations in image quality due to magnetic field inhomogeneity, which hampers precise T staging.\n\nThis study aims to compare the image quality and T staging accuracy of C-DWI, TSE-DWI, and ZOOMit-DWI (Z-DWI) sequences in MRI examinations of gastric cancer patients.\n\nA prospective study plan to enroll 72 gastric cancer patients undergoing preoperative MRI with C-DWI, TSE-DWI, and Z-DWI sequences using a 3.0 T scanner. Quantitative metrics (ADC, SNR, CNR) and image quality were evaluated. T staging accuracy was assessed by comparing MRI results with postoperative pathological staging using ROC analysis.",[201],"2024-12-13",{"date":275,"type":32},"2024-12-16",{"date":277,"type":32},"2023-12-23",{"date":279,"type":21},"2024-12-31",{"name":38,"class":39},{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":267,"sex":139,"minAge":17,"maxAge":18,"enrollmentInfo":287,"targetDuration":4,"studyType":22,"phases":289,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":61},"100572580","feasibility-study-of-deep-learning-based-mdixon-quant-for-quantitative-assessment-of-chemotherapy-induced-fatty-liver-100572580","NCT06735118","Feasibility Study of Deep Learning-based MDixon Quant for Quantitative Assessment of Chemotherapy-induced Fatty Liver","Inclusion Criteria:\n\n1. CT\u002FB ultrasound showed no fatty liver\n2. No MRI contraindications, including pacemaker, stent, metal implant, or claustrophobia\n3. Received neoadjuvant\u002Fadjuvant chemotherapy\n\nExclusion Criteria:\n\n1. Missing follow-up information\n2. Liver lesions (metastases, hemangioma, etc.)\n3. Poor image quality",{"count":288,"type":21},120,[24],"The purpose of this study is to quantitatively assess the changes in liver fat content in cancer patients before and after treatment.\n\nThe main questions it aims to answer are:How does the liver fat fraction change before and after chemotherapy? In this study, patients undergoing mDixon Quant scanning are subjected to fully automated segmentation and measurement of liver fat content using artificial intelligence.",[292],"Non-Alcoholic Fatty Liver Disease",{"date":275,"type":32},{"date":295,"type":32},"2023-12-25",{"date":297,"type":21},"2024-12-30",{"name":38,"class":39},{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":303,"acronym":85,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":87,"enrollmentInfo":305,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":306,"conditions":307,"keywords":308,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":61},"100570893","tumor-targeted-nir-ii-fluorescent-molecular-probes-for-the-identification-of-breast-cancer-tissue-and-sln-metastatic-status-100570893","NCT06713161","Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status","Inclusion Criteria:\n\n* Adult patients between 18-75 years of age\n* Female\n* Patients presenting with a breast nodule or mass presumed to be resectable on pre-operative assessment\n* Good operative candidate\n* Subject capable of giving informed consent and participating in the process of consent\n\nExclusion Criteria:\n\n* Patients unable to participate in the consent process\n* Patients had contraindications to surgery, such as serious cardiopulmonary disease, coagulation dysfunction, etc\n* Other conditions that the researcher considers inappropriate to participate in the study",{"count":113,"type":21},"Accurate evaluation of tumor boundaries in breast-conserving surgery is closely associated with reducing the second operation of patients. Meanwhile, accurately assessing sentinel lymph node (SLN) metastasis is crucial for determining the extent of axillary lymph node dissection (ALND) and minimizing complications. Near-infrared-II (NIR-II) fluorescence imaging using molecular agents has shown promise for in situ imaging during resection. However, very effective probes can be applied to clinical trials up to now, which limits the clinical application of fluorescence imaging. Here we developed a new technology that can quickly differentiation between cancer and para-cancer tissue as well as metastatic and normal sentinel lymph nodes(SLN). In brief, the fresh tissues were incubated with the probe immediately after intraoperative resection and imaged to identify the tumor area and distinguish the metastatic status of SLN. The accuracy of fluorescence imaging was confirmed by pathological diagnosis.",[51,94,117,118],[85,51,94,309,117],"Surgical Navigation","2024-11-27",{"date":312,"type":32},"2024-12-03",{"date":314,"type":32},"2024-09-01",{"date":316,"type":21},"2025-12-25",{"name":38,"class":39},{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":11,"sex":139,"minAge":17,"maxAge":87,"enrollmentInfo":324,"targetDuration":326,"studyType":90,"phases":4,"briefSummary":327,"conditions":328,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":4},"100553443","evaluation-of-axillary-lymph-node-metastasis-status-of-breast-cancer-based-on-pathological-images-and-virtual-staining-100553443","NCT06486155","Evaluation of Axillary Lymph Node Metastasis Status of Breast Cancer Based on Pathological Images and Virtual Staining","Inclusion Criteria:\n\nPart 1:\n\nFemale patients aged 18-75 with breast cancer; Undergoing surgical excision of breast cancer and sentinel lymph node biopsy\u002Faxillary lymph node dissection; Lymph nodes with clear postoperative paraffin pathological results.\n\nPart 2:\n\nPatients aged 18-75 with one of the following cancers: thyroid, lung, esophagus, stomach, colorectal, prostate, bladder, or cervix; Undergoing surgical resection of lymph nodes; Lymph nodes with clear postoperative paraffin pathological results.\n\nPart 3:\n\nFemale patients aged 18-75 with breast cancer; Undergoing surgical excision of breast cancer and sentinel lymph node biopsy; Sentinel lymph nodes with clear postoperative paraffin pathological results.\n\nExclusion Criteria:\n\nPart 1 \u002F Part 2:\n\nLymph node diagnosis is missing; Absence of lymph node component in the slice.\n\nPart 3:\n\nSentinel lymph node diagnosis is missing; Absence of lymph node component in the frozen slice.",{"count":325,"type":21},2200,"5 Years","The goal of this observational study is to develop an artificial intelligence model to transform unstained lymph node tissue slice images directly into stained images. The main questions it aims to answer are:\n\nCan the virtual staining model generate hematoxylin and eosin (H\\&E) and immunohistochemistry (IHC) images suitable for clinical diagnosis from unstained paraffin-embedded lymph node slice images, including those from breast axillary lymph nodes and other tumor lymph nodes?\n\nCan the virtual staining model generate H\\&E and IHC images suitable for clinical diagnosis from unstained frozen sentinel lymph node slice images from breast cancer patients?\n\nResearchers will retrospectively collect paraffin-embedded lymph node slices from tumor patients and prospectively collect frozen sentinel lymph node slices from breast cancer patients.",[329,330,51,331],"Virtual Staining","Lymph Node Metastasis","Digital Pathology","2024-08-10",{"date":334,"type":32},"2024-08-13",{"date":336,"type":21},"2024-08",{"date":338,"type":21},"2025-12",{"name":38,"class":39},{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":87,"enrollmentInfo":347,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":349,"conditions":350,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":352,"startDateStruct":353,"completionDateStruct":354,"leadSponsor":355,"locationsCount":4},"100555334","prediction-of-non-sentinel-lymph-node-metastatic-status-of-breast-cancer-based-on-pathology-mri-images-100555334","NCT06510738","Prediction of Non-sentinel Lymph Node Metastatic Status of Breast Cancer Based on Pathology-MRI Images","Prediction of Non-sentinel Lymph Node Metastatic Status of Breast Cancer Based on Pathology-MRI Images and Artificial Intelligence","Inclusion Criteria:\n\n1. Patients with primary breast cancer\n2. Positive sentinel lymph node biopsy and axillary lymph node dissection.\n3. No neoadjuvant chemotherapy, radiotherapy or ablation prior to surgery.\n4. MRI within 3 weeks prior to surgery.\n\nExclusion Criteria:\n\n1. recurrent breast cancer or history of surgery or radiation therapy in the axilla\n2. Inflammatory breast cancer\n3. Bilateral breast cancer or metastatic breast cancer\n4. previous or current history of other malignant tumors\n5. Sentinel lymph node count \\> 5",{"count":348,"type":21},700,"The goal of this observational study is to develop an artificial intelligence model based on pathology and magnetic resonance imaging (MRI) images to predict the metastatic status of non-sentinel lymph nodes in patients with breast cancer sentinel lymph node metastasis. The main questions it aims to answer are:\n\nCan an artificial intelligence model based on MRI images of breast cancer patients predict the non-sentinel lymph node metastatic status in patients with breast cancer sentinel lymph node metastasis?\n\nCan an artificial intelligence model based on intraoperative frozen section images of sentinel lymph nodes in breast cancer patients predict the non-sentinel lymph node metastasis status in patients with sentinel lymph node metastasis from breast cancer?\n\nCan artificial intelligence models based on preoperative MRI and intraoperative frozen section images of sentinel lymph nodes in breast cancer patients predict the non-sentinel lymph node metastatic status in patients with sentinel lymph node metastasis from breast cancer?\n\nResearchers will retrospectively and prospectively collect preoperative MRI and intraoperative sentinel lymph node section images from breast cancer patients.",[51,351,330,331],"Artificial Intelligence",{"date":334,"type":32},{"date":336,"type":21},{"date":338,"type":21},{"name":38,"class":39},{"id":357,"slug":358,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":22,"phases":364,"briefSummary":365,"conditions":366,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":61},"100554180","application-of-rapid-on-site-evaluation-in-lymph-node-biopsy-of-breast-cancer-100554180","NCT06495736","Application of Rapid On-site Evaluation in Lymph Node Biopsy of Breast Cancer","Inclusion Criteria:\n\n* Patients had pathologically confirmed primary breast cancer\n* Surgical treatment was available\n\nExclusion Criteria:\n\n* Previous history of surgery on the affected axilla, internal breast or chest\n* Pregnant or breastfeeding patients\n* Previous radiotherapy or chemotherapy\n* Complicated history of other tumors",{"count":363,"type":21},400,[24],"The goal of this clinical trial is to evaluate the value of rapid on-site evaluation（ROSE） in lymph node biopsy of breast cancer. The main question it aims to answer is:The ROSE technique was applied to breast cancer lymph node biopsy to improve the diagnostic efficiency and accuracy.\n\nParticipants underwent routine lymph node biopsy, and the test personnel conducted routine disease examination and rose technique evaluation on the removed ly",[51],"2024-07-02",{"date":369,"type":32},"2024-07-11",{"date":371,"type":32},"2024-02-01",{"date":373,"type":21},"2026-02",{"name":38,"class":39},{"id":376,"slug":377,"hasResults":11,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":11,"sex":139,"minAge":17,"maxAge":87,"enrollmentInfo":383,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":61},"100552815","the-efficacy-of-watch-and-wait-strategy-or-surgery-after-neoadjuvant-immunotherapy-for-locally-advanced-colorectal-cancer-with-dmmrmsi-h-guided-by-mrd-dynamic-monitoring-a-single-center-open-label-prospective-phase-ii-clinical-trial-100552815","NCT06477991","The Efficacy of Watch and Wait Strategy or Surgery After Neoadjuvant Immunotherapy for Locally Advanced Colorectal Cancer With dMMR\u002FMSI-H Guided by MRD Dynamic Monitoring: A Single-center, Open-label, Prospective, Phase II Clinical Trial.","The Efficacy of Watch and Wait Strategy or Surgery After Neoadjuvant Immunotherapy for Locally Advanced Colorectal Cancer With dMMR\u002FMSI-H Guided by MRD Dynamic Monitoring(WINDOW): A Single-center, Open-label, Prospective, Phase II Clinical Trial.","WINDOW","Inclusion Criteria:\n\n* ( 1 ) Disease characteristics 1. Histologic confirmation for colorectal adenocarcinoma; 2．Immunohistochemical identified as dMMR and\u002For pCR and\u002For NGS detection for MSI-H; 3．According to UICC\u002FAJCC TNM staging system (in 2017 version 8) assessment for locally advanced colorectal cancer (II - III, namely cT3-4 and\u002For N + ）； 4.\\* clinical staging methods: colon CT staging, approved by pelvic magnetic resonance imaging (MRI) and the rectum rectum cavity ultrasound combined with staging, 5．No signs of intestinal obstruction;Or intestinal obstruction after proximal colon obstruction has been relieved after colostomy surgery; 6．No distant metastasis was confirmed by comprehensive examination (distant organs or (and) the distant lymph node metastasis); ( 2 ) Previous treatment 1．No colorectal cancer surgery before; 2. No previous chemotherapy or radiotherapy ; 3. had not received biological treatment ; 4. Previous endocrine therapy : no restriction.\n\nExclusion Criteria:\n\n* 1.Immunohistochemistry of tumor biopsy specimens suggested pMMR or microsatellite instability detection suggested MSS ; 2. Chronic hepatitis B or C ( high-copy viral DNA ) with a history of HIV infection or active phase ; 3.Autoimmune diseases ; 4.Other active clinical severe infections ( \\> NCI-CTC3.0 version ) ; 5. patients with clinical stage I ; 6.Preoperative evidence of distant metastasis ; 7. cachexia, organ dysfunction ; 8. Have a history of pelvic or abdominal radiotherapy ; 9. Patients whose seizures require treatment ( e.g. steroids or antiepileptic treatment ) ; 10.5 years have a history of other malignant tumors, except for cured cervical carcinoma in situ or skin basal cell carcinoma ; 11. Chronic inflammatory bowel disease, intestinal obstruction ; 12. Drug abuse and medical, psychological or social conditions may interfere with patient participation in the study or have an impact on the evaluation of the results of the study ; 13.Known or suspected allergies to the study drug or any drug related to this test ; any unstable condition or condition that may endanger patient safety and compliance ;",{"count":384,"type":21},22,"This study is a single arm, single center, phase II, prospective clinical study aimed at exploring the effectiveness and safety of watch and wait strategy guided by dynamic minimal disease residual (MRD) monitoring to achieve clinical complete response after neoadjuvant immunotherapy for locally advanced colorectal cancer with deficient mismatch repair\u002F microsatellite instability-high (dMMR\u002FMSI-H).",[387],"Clinical Complete Response Rate With Negative MRD","2024-06-21",{"date":390,"type":32},"2024-06-27",{"date":392,"type":32},"2023-10-30",{"date":394,"type":21},"2026-10-30",{"name":38,"class":39},""]